Introduction
Glycogen synthase kinase 3 (GSK3) was originally identified as a Ser-/Thr-protein kinase which phosphorylates and inhibits glycogen synthase [1] . In the preprandial or fasted state, GSK3 is catalytically-active and glycogenolysis predominates. On feeding, the insulinstimulated phosphorylation and consequent inhibition of GSK3 assists in promoting glycogen synthesis and accumulation [2] . In this case, inhibition of GSK3 is mediated by the signalling pathway which involves phosphoinositide 3-kinase (PI3K), 3-phosphoinositidedependent kinase 1 (PDK1) and protein kinase B/Akt (PKB/Akt). However, it is now recognised that GSK3 plays a much wider role in biological processes [3] [4] [5] [6] [7] . For example, it is central to the developmentally-important Wnt/Frizzled/$-catenin pathway and this function appears to be largely separate from its role in the regulation of glycogen metabolism [8] [9] [10] .
Mammalian cells express two isoforms of GSK3 which exhibit a high degree of sequence similarity in their catalytic domains, GSK3" (molecular mass ~ 51 kDa) and GSK3$ (molecular mass ~ 47 kDa). GSK3 is phosphorylated on at least two residues. There are 'facilitative' autophosphorylations of GSK3"(Tyr-279) and GSK3$(Tyr-216) required for GSK3 activity [11] [12] [13] , and there are regulatory phosphorylations of GSK3"(Ser-21) and GSK3$(Ser-9) which inhibit its kinase activity [3] [4] [5] [6] [7] . PKB/Akt phosphorylates GSK3"(Ser-21) and GSK3$(Ser-9), and these residues lie in a typical PKB/Akt consensus substrate motif [14] . However, GSK3"(Ser-21)/GSK3$(Ser-9) are phosphorylated by other kinases which also recognise the "PKB/Akt consensus sequence". These include particularly the p70/p85-ribosomal protein S6 kinases (S6K1 and S6K2) and the p90-ribosomal protein S6 kinases (RSK1-4) [4, 5, 7, 15] . The active form of GSK3 phosphorylates its substrates in a 'relay' fashion which requires an initial 'priming' phosphorylation at a Ser-/Thr-residue lying four residues C-terminal (+4) to the Ser-/Thr-phosphorylated by GSK3, and this 'priming' phosphorylation is catalysed by one of several protein kinases [7] . The Ser(P)/Thr(P) initially phosphorylated by GSK3 can serve subsequently as a priming phosphorylation for any Ser-/Thr-residue lying in the -4 position. These relays can be extended. For example, four GSK3 sites and a priming site are present between residues 641-657 in Homo sapiens muscle glycogen synthase.
GSK3 is important in Wnt-dependent cardiac development and growth [16] .
However, it has also been implicated in adaptive growth of the postnatal heart [17] [18] [19] [20] [21] . The mammalian cardiac myocyte withdraws from the cell cycle in the perinatal period but expands in size during the maturational growth of the organism. In addition to maturational growth, cardiac myocytes can undergo adaptive, hypertrophic growth in vivo or ex vivo in response to an increase in cardiac workload [22, 23] , or to stimulation of a variety of transmembrane receptors (e.g. the endothelin ET A receptor or the " 1 -adrenergic receptor) [24] [25] [26] [27] . In vivo, myocardial hypertrophy (to which the expanded cardiac myocytes contribute) is a major adaptive response which allows the heart to accommodate any physiological or pathological increase in loading that it encounters. However, in chronic pathological overloading (e.g. in hypertension), this adaptive phase may ultimately degrade into the maladaptive state of heart failure [23, 28] . One proposal is that catalytically-active GSK3 inhibits the development of hypertrophy in the unstimulated myocyte, and inhibition of GSK3 (particularly GSK3$) through PI3K-dependent signalling leads to hypertrophy [17] [18] [19] [20] [21] .
Although GSK3 may participate in the cardiac myocyte hypertrophy induced by Gq-coupled protein receptor (GqPCR) agonists such as endothelin-1 (ET-1) acting at the ET A receptor and adrenergic receptor agonists [17, 18] , it is by no means the only signalling protein implicated in the response. Others proteins/pathways include the extracellular signal-5 regulated kinase 1 and 2 (ERK1/2) cascade, other mitogen-activated protein kinase cascades, and Ca 2+ -dependent signalling pathways [29] [30] [31] [32] [33] [34] . Furthermore, ERK1/2 phosphorylate and activate RSKs [35] , for which GSK3 is a known substrate [15] . Here, we demonstrate differential signalling to GSK3 from ET-1 and insulin, and we characterise the morphological and transcriptional changes induced in cardiac myocytes by inhibiting GSK3 with a small molecule inhibitor, 1-azakenpaullone [36] .
Materials and methods

Materials
Polyclonal antibodies to GSK3" and phospho-GSK3"(Ser-21)/phospho-GSK3$(Ser-9), and the monoclonal antibody to GSK3$ were from Cell Signaling Technology (catalogue nos. 9338, 9331 and 9315, respectively). The monoclonal antibody to phospho-GSK3$(Tyr-216), which also cross-reacts with phospho-GSK3"(Ser-279), was from BD Transduction 
Primary culture of neonatal rat cardiac myocytes and preparation of whole cell extracts
Myocytes were dissociated from the ventricles of 1-to 3-day-old Sprague-Dawley rat hearts by an adaptation of the method of Iwaki et al. [26] as previously described [37] .
Unless stated otherwise, cells were plated at a density of 4 × 10 6 cells/60 mm Primaria culture dish (BD Biosciences) for 18 h in 15% (v/v) foetal calf serum, then serum was withdrawn for the 24 h before experimentation. Myocytes were exposed to ET-1 (100 nM), PMA (1 :M) or insulin (50 mU/ml, 300 nM) with or without pre-treatment (for 10 min) with inhibitors. 
Preparation of nuclear extracts
Nuclear extracts were prepared as previously described [38] . Liquid Chromatography (FPLC) fractions] were separated by SDS-polyacrylamide gel electrophoresis using 10% (w/v) resolving gels and 6% (w/v) stacking gels, and transferred to nitrocellulose as described previously [40] . Non-specific binding sites were blocked with 5% 
Fast protein liquid chromatography (FPLC)
Myocytes ( were eluted using a linear NaCl gradient (0.1 -0.3 M NaCl, 10 ml) at a flow rate of 1 ml/min with collection of 0.5 ml fractions. Samples from each fraction were assayed for GSK3 :l of the reaction mixture onto Whatman P81 papers which were then washed in 75 mM H 3 PO 4 (4 × 15 min). Radioactivity incorporated was determined by "erenkov counting.
GSK3 activity was taken as the difference in 32 P incorporation between assay in the absence and presence of 1-azakenpaullone. 
Immunostaining and planimetry
Glass
Electrophoretic mobility shift assays (EMSAs)
An oligonucleotide probe containing the consensus AP1 sequence (5'-CGCTTGATGACTCAGCCGGAA-3', AP1 sequence underlined, Santa Cruz Biotechnology Whatman 3MM paper and exposed to Hyperfilm MP for 24 -48 h at -80/C. For supershift assays, nuclear extracts (3 :g protein) were pre-incubated (1 h , 4/C) with 1-2 :g of primary antibody and EMSAs then performed as described.
RNA preparation and microarray analysis.
Myocytes (4 × 10 performed for each condition (i.e. 9 myocyte preparations in total). Fragmentation of antisense cRNA and hybridisation to Affymetrix rat genome 230 2.0 arrays were performed at the CSC Microarray Centre (Hammersmith Campus, Imperial College London) according to their standard protocols (microarray.csc.mrc.ac.uk). The MIAME-compliant data were exported to ArrayExpress (E-MIMR-681). Preliminary analysis of hybridisation data was with Affymetrix GeneChip Operating System, GCOS. The data were imported into GeneSpring GX 7.3.1 (Agilent Technologies) as tab-delimited text files. Log 10 values were used for analysis with values set to a minimum of 0.01 and, for each data-set, the data were normalised per array (to the 50th percentile) and values for each probe set were normalised to the corresponding controls (prepared and hybridised simultaneously). A confidence filter was applied and genes were selected if present or marginal in all controls, all samples from myocytes exposed to 1-azakenpaullone or all samples from myocytes exposed to ET-1.
One-way non-parametric t-tests were performed for each transcript for each condition relative to the appropriate controls (GeneSpring GX). The false discovery rate was set to <0.05 and multiple testing correction performed using the Benjamini and Hochberg false discovery rate algorithm. Transcripts were filtered on the basis of >2-fold difference. All genes were confirmed by BLAST search and were correct as of August 2007.
Quantitative PCR (qPCR)
RNA was extracted and cDNA synthesized using reverse transcription as previously described [42] . qPCR was performed using a Real-Time PCR System model 7500 (Applied products (e.g. primer-dimers).
Densitometry and statistical analysis
For immunoblots and EMSA autoradiographs, bands were quantified by scanning densitometry using Imagemaster 1D calibrated with Kodak photographic step tablet no. 2 (GE Healthcare). Statistical analysis was performed using GraphPad Prism. One-way ANOVA (repeated measures where appropriate) was used with a multiple comparison test (Tukey for full multiple testing; Dunnett for testing against controls only).
Results
Stimulation of phosphorylation of GSK3"(Ser-21) and GSK3$(Ser-9) in cardiac myocytes by ET-1, PMA or insulin
Immunoblot analysis demonstrated that both GSK3" and GSK3$ are expressed in cardiac myocytes (Fig. 1A-C , lower panels). Using phosphorylation site-specific antibodies,
we showed that maximally-effective concentrations (data not shown) of ET-1 (100 nM), PMA (1 :M) or insulin (300 nM) promoted rapid increases (maximal in 2-5 min) in the phosphorylation of GSK3"(Ser-21) and GSK3$(Ser-9) ( GSK3"(Ser-21)/GSK3$(Ser-9) may be phosphorylated by a variety of protein kinases lying downstream from either PI3K (i.e. PKB/Akt) or the ERK1/2 cascade (e.g.
RSKs) [4, 5, 7] . U0126 and LY294002 are widely used as inhibitors of the ERK1/2 cascade [43] and of PI3K [44] , respectively. U0126 reduced the phosphorylation of GSK3"(Ser- 21) and GSK3$(Ser-9) stimulated by ET-1 ( Fig. 2A, D and E) or PMA (Fig. 2B , D and E), whereas LY294002 was largely ineffective. Conversely, LY294002 reduced the phosphorylation of GSK3"(Ser-21) and GSK3$(Ser-9) stimulated by insulin (Fig. 2C , D and E), whereas U0126 was largely ineffective. Thus, ET-1 and PMA induce phosphorylation of GSK3"(Ser-21) and GSK3$(Ser-9) primarily through the ERK1/2 cascade, whereas insulin induces phosphorylation primarily through PI3K.
Phosphorylation of GSK3"(Tyr-279) and GSK3$(Tyr-216)
Phosphorylation of GSK3"(Tyr-279) and GSK3$(Tyr-216) is essential for their catalytic activity. Although there have been reports that agonists cause dephosphorylation or phosphorylation of these residues and this represents a means whereby GSK3 can be inhibited or activated in intact cells [45] [46] [47] [48] , this is not necessarily the case [7, 13, 49] . We examined the phosphorylation of GSK3"(Tyr-279) and GSK3$(Tyr-216) in cardiac myocytes. The monoclonal antibody to phospho-GSK3$(Tyr-216) cross-reacts with phospho-GSK3"(Ser-279), presumably because the amino acid sequences of residues 190-305 in rat GSK3$ (accession no. NP_114469) and residues 253-368 in rat GSK3" (accession no. NP_059040) are identical. We detected phospho-GSK3"(Tyr-279) and phospho-GSK3$(Tyr-216) in approximately equal apparent abundances (Fig. 3A-C) . Assuming that the affinity of the monoclonal antibody for both GSK3 isoforms is similar (because of the sequence identity) and that GSK3"(Tyr-279) and GSK3$(Tyr-216) are stoicheiometrically phosphorylated [13] , this suggests that GSK3" contributes significantly to the GSK3 complement in cardiac myocytes and cannot be ignored. However, there were not any changes in the phosphorylation of GSK3"(Tyr-279) or GSK3$(Tyr-216) in cardiac myocytes treated with ET-1 (Fig. 3A) , PMA (Fig. 3B) or insulin (Fig. 3C ) over 30 min.
The phosphorylation of GSK3"(Tyr-279) and GSK3$(Tyr-216) probably represents autophosphorylation. Chemical inhibition of GSK3 leads to dephosphorylation of GSK3"(Tyr-279) and GSK3$(Tyr-216) in other cells [7, 13] . In cardiac myocytes exposed to the GSK3 inhibitor, 1-azakenpaullone (10 :M) [36] , the total pool of GSK3$ did not change, but phospho-GSK3"(Tyr-279) and phospho-GSK3$(Tyr-216) declined over a 12 h period ( Fig. 3D and E) . Phospho-GSK3"(Tyr-279) was apparently more rapidly dephosphorylated than phospho-GSK3$(Tyr-216). These data are consistent with the view that phosphorylation of GSK3"(Tyr-279) and GSK3$(Tyr-216) represents an autophosphorylation [7, 13] . However, we do not know the mechanism of the dephosphorylation, nor do we understand its differential nature for the two GSK3 isoforms.
Dephosphorylation (Fig. 3D and E) could represent a genuine dephosphorylation as a result of protein Tyr-phosphatase activity. Alternatively, turnover of phospho-GSK3"(Tyr-279) and phospho-GSK3$(Tyr-216) proteins through protein degradation and resynthesis of GSK3 in the absence of autophosphorylation would lead to apparent dephosphorylation. In this regard, Cole et al. [13] have presented data with protein synthesis inhibitors suggesting that the dephosphorylation reflects a genuine phosphatase activity rather than protein turnover.
Fast Protein Liquid Chromatography separation of GSK3
GSK3"/GSK$ were partially purified by MonoS FPLC of cardiac myocyte extracts from unstimulated cells and from cells exposed to ET-1 or insulin. Column fractions were assayed GSK3 activity and immunoblotted for phospho-GSK3"(Tyr-279)/phospho-GSK3$(Tyr-216), phospho-GSK3"(Ser-21)/phospho-GSK3$(Ser-9) and total GSK3$ (Fig.   4 ). GSK3 activity eluted as a broad peak between 0.11 -0.22 M NaCl (fractions 11-20) with a small shoulder (particularly apparent using control extracts) in fractions 13-14 (Fig. 4A) .
Total GSK3 activities (obtained by integrating areas under the peaks) were reduced by 54.2 ± 1.4% with insulin and 31.9 ± 6.4% with ET-1 (Fig. 4B) . Thus, both insulin and ET-1 inhibit GSK3, but perhaps not to the extent that might have been anticipated.
Antibodies to phospho-GSK3"(Tyr-279)/phospho-GSK3$(Tyr-216) proved effective for the detection of total GSK3 (i.e. both isoforms) by immunoblotting (Fig. 4C ) and were used routinely for this purpose. Although total GSK3$ antibodies were satisfactory for detecting protein in FPLC fractions, total GSK3" antibodies did not detect any bands.
Phospho-GSK3"(Tyr-279) eluted predominantly in fractions 12-17, with phospho-GSK3$(Tyr-216) eluting in fractions 14-20 (Fig. 4C) . GSK3$ immunoreactivity reflected phospho-GSK3$(Tyr-216) immunoreactivity (Fig. 4D) . Thus, GSK3$ probably constitutes the majority of GSK3 activity in fractions 15-19 (Fig. 4A) , and may indeed constitute the majority of GSK3 activity overall. GSK3" probably accounts for the shoulder of GSK3 activity in fractions 13-14 (Fig. 4A) . A significant proportion of phospho-GSK3"(Tyr-279)/phospho-GSK3$(Tyr-216) (or total GSK3$) eluted in fractions 2-4 of the isocratic wash (Fig. 4C ), but there was no detectable GSK3 activity (data not shown). This pool of GSK3 did not bind to MonoS columns even in the total absence of any NaCl in the extraction buffer (myocytes were routinely extracted in 0.1 M NaCl). There were no gross changes in the elution profiles of phospho-GSK3"(Tyr-279) or phospho-GSK3$(Tyr-216) (or, indeed, total GSK3$) in cells treated with ET-1 or insulin.
The phospho-GSK3"(Ser-21)/phospho-GSK3$(Ser-9) antibodies detected little immunoreactivity in FPLC fractions from control extracts, but immunoreactivity was readily detected in fractions 13-18 using extracts of myocytes exposed to ET-1 or insulin (Fig. 4E) .
We directly compared fractions obtained from control myocytes and myocytes exposed to ET-1 or insulin (Fig. 4F ). ET-1 or insulin increased phospho-GSK3"(Ser-21)/phospho-GSK3$(Ser-9) (relative to controls) in the fractions from the isocratic wash and in gradient fractions 16-18, with insulin having the greater effect. The increase in phospho-GSK3"(Ser-21)/phospho-GSK3$(Ser-9) immunoreactivity in fractions 2-3 ( Fig. 4E and F) implies that phosphorylation of GSK3"(Ser-21) and GSK3$(Ser-9) in this pool can be increased over control values. Thus, the absence of GSK3 activity in fractions 2-3 does not result from the fact that GSK3"(Ser-21) and GSK3$(Ser-9) in these fractions are already fully phosphorylated.
Subcellular localisation of GSK3 and the morphological effects of its inhibition in cardiac myocytes
Subcellular localisation of GSK3 was assessed by immunostaining with antibodies to phospho-GSK3"(Tyr-279)/phospho-GSK3$(Tyr-216) with counterstaining of nuclei by
Hoechst 33258 (Fig. 5A and B) . Myocyte identity was confirmed by troponin T immunostaining (data not shown). Phospho-GSK3"(Tyr-279)/phospho-GSK3$(Tyr-216)
immunostaining was strongest in myocyte nuclei, with considerably less in the cytoplasm (Fig. 5A ). There were no gross changes in phospho-GSK3"(Tyr-279)/phospho-GSK3$(Tyr-216) localisation in cells exposed to ET-1 or insulin for 20 min (data not shown).
We compared the effects of inhibitors of GSK3 (1-azakenpaullone or LiCl) and the "-adrenergic agonist, phenylephrine (a powerful hypertrophic agonist) on cardiac myocyte morphology. Phenylephrine promoted increased cardiac myocyte area (Fig. 5C and D) . This was associated with increases in maximum cell length and width (Fig. 5E and F) such that the maximum length:maximum width ratio was increased to only a small extent compared with controls (Fig. 5G) . Cardiac myocyte area was also increased by 1-azakenpaullone (Fig. 5C ), but this primarily reflected increased cell length in the absence of any increase in cell width ( Fig. 5E and F) . Consequently, the maximum length:maximum width ratio was significantly increased (Fig. 5G ). There was a small increase (42 ± 5 %) in the area of cells exposed to LiCl (Fig. 5D ), but this did not reach statistical significance.
Transcription factor binding to the AP1 consensus sequence
The AP1 transcription factor complex is a homodimer of Jun family members (c-Jun, JunB and JunD) or a heterodimer of Jun family members and Fos family members (c-Fos, FosB, Fra1 and Fra2), though not all combinations are allowed [50, 51] . GSK3
phosphorylates the C-terminal regions of Jun family transcription factors at sites proximal to their DNA binding domains, and this decreases their affinity for AP1 consensus sequences and their transactivating potential [52] . Conversely, inhibition of GSK3 and dephosphorylation of the GSK3 sites in the Jun family increases their transactivating potential. We examined the abilities of 1-azakenpaullone, insulin and ET-1 to increase binding of nuclear proteins to an AP1 oligonucleotide using EMSAs (Fig. 6A and B) . ET-1 was the most effective agonist, but both 1-azakenpaullone and insulin were moderately effective ( Fig. 6A and B) . Antibodies to JunB clearly supershifted the bands after exposure of cells to each of the three agonists (Fig. 6C ). Antibodies to other potential AP1 components produced a subshift (c-Fos) or reduced binding (for FosB, JunD or Fra2)
suggesting that they may be involved, but there was no consistency between the three agonists.
Increased binding of JunB to AP1 sequences could reflect an increase in abundance or an increase in affinity caused by a reduction in phosphorylation of Ser-/Thr-residues proximal to the C-terminal DNA region. 1-Azakenpaullone (Fig. 6D) or insulin (Fig. 6E) increased the abundances of JunB within 1 h, which may well explain the increase in binding to AP1 (Fig. 6A-C) . By analogy with human JunB [52] , rat JunB should contain GSK3 phosphorylation sites at Ser-248 and Thr-252, the priming phosphorylation being on Ser-256.
We do not know whether there is a decrease in phosphorylation of these residues as well as an increase in abundance following inhibition of GSK3. The only available phosphopeptide antibody detects the priming phosphorylation (Ser-259 in Homo sapiens JunB). Not unexpectedly, we were unable to detect any changes in the phosphorylation state of this residue with 1-azakenpaullone, insulin or ET-1 (data not shown).
Changes in gene expression
Since GSK3 appears to be localised predominantly to the nucleus in cardiac myocytes (Fig. 6D ) may therefore reflect decreased degradation of JunB protein.
To validate the changes in gene expression induced by 1-azakenpaullone, we used qPCR to examine a more detailed time course for expression of prostaglandin-endoperoxide synthase 2 (Ptgs2, also known as cyclooxygenase 2), cyclin G2 (Ccng2) and adrenomedullin.
Consistent with the microarray data ( Table 1) , expression of Ptgs2 mRNA was increased at 60 min (Fig. 7A ). This increase was transient and expression declined almost to basal levels by 2 h. Ccng2 (Fig. 7B) and adrenomedullin (Fig. 7C ) mRNAs were both decreased in expression with maximal decreases occurring at 60 -90 min.
Discussion
In addition to participating in the Wnt/Frizzled pathway during cardiac development [16] , inhibition of GSK3 has recently been implicated in the development of cardiac hypertrophy [20, 21] . In cultured cardiac myocytes, $-adrenergic stimulation induces aspects of the hypertrophic response in a manner dependent on the activation of PI3K and PKB/Akt, and the subsequent inhibition of GSK3$ [17] . Similar conclusions have been drawn with ET-1 or phenylephrine as agonists, or by using chemical inhibition of GSK3 with LiCl [18] .
These ex vivo observations were extended with the in vivo finding that raising left intraventricular pressure by transverse aortic constriction (TAC, a pro-hypertrophic intervention) inhibits GSK3 activity [18] . Furthermore, a transgenic mouse in which a 22 constitutively-active (non-phosphorylatable) form of GSK3$ [GSK3$(Ser-9Ala)] is cardiospecifically expressed showed reduced hypertrophy in response to overexpression of constitutively-active calcineurin, infusion of isoprenaline or TAC [19] . There were no obvious effects of GSK3$(Ser-9Ala) in unmanipulated control mice (although others have reported that cardiospecific overexpression of wild type GSK3$ impairs post-natal growth of cardiac myocytes [53] ). Thus, stimulation of the catalytic activity of GSK3 could represent an anti-hypertrophic intervention, possibly with therapeutic potential. Potentially contrasting with the proposed anti-hypertrophic action, a pro-apoptotic role of GSK3 activation has been identified in adult cardiac myocytes [48] and other cells [54] . Furthermore, cardiospecific overexpression of wild-type GSK3$ causes contractile dysfunction, possibly as a result of disturbances in Ca 2+ movements [53] . These experiments [48, 53] suggest that activation of GSK3 might be deleterious. However, it is worth noting that, in vivo, replacement of the wild-type GSK3" and GSK3$ genes with transgenes encoding constitutively-active GSK3" and GSK3$ [GSK3"(Ser21Ala)/GSK3$(Ser9Ala) 'knock-in' mice] does not appear to interfere with survival or baseline cardiac function [55, 56] . In this situation, the fully-active mutant proteins in the 'knock-in' situation are expressed in the same abundances as the wildtype proteins in the wild-type animals, thus simulating the in vivo situation, rather than being overexpressed.
Here, we have extended the characterisation of GSK3 in the heart. Past reports have emphasised a predominant role for GSK3$ (as opposed to GSK3") in cardiac myocyte hypertrophy. However, both isoforms are clearly expressed (Fig. 1A-C) . Assuming that the phospho-GSK3$(Tyr-216) antibody has similar affinity for phospho-GSK3"(Tyr-279) as for with anti-phospho-GSK3$(Tyr-216) suggests that GSK3$ activity predominates over GSK3" activity by a factor of 5-to 10-fold (Fig. 4A and C) . However, the catalytic activity of GSK3" is probably important in the heart. Unlike the situation in skeletal muscle where GSK3$ activity seems the more important [55] , GSK3" does participate significantly in the regulation of cardiac glycogen metabolism [56] . It is not known whether there is any GSK3
isoform specificity in terms of additional functional consequences in the heart. In whole animals and isolated cells, both similarities and differences between GSK3" and GSK3$ have been detected [55] [56] [57] [58] . We therefore believe that a role for both GSK3" and GSK3$ particularly in myocyte hypertrophy should be considered.
Published studies emphasise the importance of PKB/Akt in the phosphorylation and inhibition of GSK3 by hypertrophic GPCR agonists [17, 18, 59] . However, GSK3 may be phosphorylated by other protein kinases. In cardiac myocytes, ET-1 and PMA rapidly and powerfully activate ERK1/2 [60] whereas they only weakly activate PKB/Akt [61, 62] .
Conversely, insulin is a powerful activator of PKB/Akt, but is ineffective in activating ERK1/2 [62, 63] . Thus, the separate roles of these two signalling pathways can be partially delineated in cardiac myocytes by the use of these 'selective' agonists. Insulin at maximallyeffective concentrations causes the largest increase in phosphorylation of GSK3"(Ser-21)/GSK3$(Ser-9), with ET-1 or PMA being approximately half as effective (Fig. 1F and G) implying that PKB/Akt mediates insulin-stimulated phosphorylation of GSK3 and ERK1/2 mediate phosphorylation in response to ET-1 or PMA. Consistent with this, U0126 inhibits the phosphorylation of GSK3"(Ser-21) and GSK3$(Ser-9) induced by ET-1 or PMA, but not insulin (Fig. 2) . Conversely, LY294002 inhibits phosphorylation of GSK3"(Ser-21) and GSK3$(Ser-9) induced by insulin, but not ET-1 or PMA (Fig. 2) . Although potential problems relating to inhibitor specificity cannot be excluded [64, 65] , we conclude that the ERK1/2 cascade is primarily responsible for phosphorylation of GSK3 induced by ET-1 or PMA (possibly via the RSKs), whereas PI3K signalling is required for that induced by insulin (presumably via PKB/Akt). Our results for ET-1 contrast with those of Haq et al. [18] who concluded that phosphorylation of GSK3$(Ser-9) involved activation of PI3K.
MonoS FPLC raises the possibility of separate pools of GSK3. Apart from the catalytically-active pool of GSK3 which eluted at 0.11 -0.22 M NaCl, we detected a pool of phospho-GSK3"(Tyr-279)/phospho-GSK3$(Tyr-216) in the isocratic wash which was catalytically inactive (Fig. 4A, C and D) . Although largely unphosphorylated on GSK3"(Ser-21)/GSK3$(Ser-9) under control conditions, this pool became phosphorylated following exposure of the cells to insulin and, to a lesser extent, ET-1 ( Fig. 4C and E) indicating that it is not inactive as a consequence of complete phosphorylation of the inhibitory Ser-residues. One explanation could be that this pool of GSK3 is inhibited by complexation with other proteins.
Catalytically-active GSK3 eluted from MonoS columns at 0.11 -0.22 M NaCl, and insulin or ET-1 increased phosphorylation GSK3"(Ser-21)/GSK3$(Ser-9), partially inhibiting this GSK3 (Fig. 4A, E and F) . Other studies used immunoprecipitation to purify GSK3 [41] for in vitro assays and similarly showed only partial inhibition of GSK3 in response to insulin or ET-1 [18] . However, such assays are known to be problematical in certain instances (K. Sakamoto, personal communication) and, although we could detect substantial GSK3$ activity (only the anti-GSK3$ antibody was suiyable for immunoprecipitation) in unstimulated cells using immunokinase assays, we were consistently unable to detect any inhibition by insulin or ET-1. This (and the partial rather than more extensive inhibition expected from our FPLC experiments) may relate to the mechanism by 25 which phosphorylation of GSK3"(Ser-21)/GSK3$(Ser-9) is inhibitory. These phosphorylations compete internally for the binding site of the priming phosphorylation on GSK3 substrates [71] . In an assay, therefore, an efficient phospho-peptide substrate such as that used here competes effectively for the same binding site. We suspect that the enzyme:substrate ratio is crucial in these assays.
The mechanisms involved in the anti-hypertrophic effects of (catalytically-active)
GSK3 are not clear [20, 21] but presumably involve regulation of gene and protein expression. Changes in gene expression may result from degradation of the transcriptional co-regulator, $-catenin [59, 66, 67] (as occurs in the Wnt/Frizzled pathway [8] [9] [10] ), nuclear exclusion of pro-hypertrophic transcription factors such as the NFATs [18, 19] and GATA4 [68] , and inhibition of the biological activity of the transcriptional co-regulator, myocardin [69] . At the level of translation, GSK3 may phosphorylate and reduce the biological activity of eukaryotic initiation factor 2B [70] . Immunostaining with antibodies to phospho-GSK3"(Tyr-279)/phospho-GSK3$(Tyr-216) (the only antibody we found to be satisfactory)
showed GSK3 staining predominantly in the nuclei, with much weaker staining in the cytoplasm (the site of glycogen metabolism) (Fig. 5A) . Thus, GSK3 could to influence gene expression through phosphorylation of nuclear transcription factors. A nuclear pool of GSK3 has been detected in other cells [54] , and nuclear GSK3 is reportedly increased by isoprenaline in adult cardiac myocytes [48] . However, we could not see any effect of insulin or ET-1 on the subcellular localisation of GSK3 in neonatal cells (data not shown).
Given the presence of GSK3 in cardiac myocyte nuclei (Fig. 5A) , and that activation of PKB/Akt with consequent inhibition of GSK3 may represent a signalling pathway that promotes the changes in gene expression associated with cardiac myocyte hypertrophy [20, 21] , we examined the potential changes in AP1 transcription factor activity induced by 26 inhibition of GSK3. GSK3 phosphorylates Jun family transcription factors at residues immediately N-terminal to their DNA binding domains and these phosphorylations negatively regulate their transactivating potentials [52] . For c-Jun, the decrease in transactivating ability may result from either decreasing DNA binding [72] or by promoting its degradation [73] . EMSAs with cardiac myocyte nuclear extracts showed that ET-1 increased binding of AP1 components to a DNA consensus sequence (Fig. 6A and B) . This resulted from an increase in several AP1 components (Fig. 6) . Although insulin or the GSK3 inhibitor 1-azakenpaullone also increased AP1 binding, this was less than that induced by ET-1 and derived principally from an increase in JunB binding. The differences between 1-azakenpaullone and ET-1 on gene expression were further highlighted in our microarray experiments. It is clear from Table 1 that, although 1-azakenpaullone does cause changes in transcript abundances (three of which were confirmed by qPCR, see Fig. 7 ), these differ from those induced by ET-1. Thus, from the perspective of gene expression, cardiac myocyte hypertrophy induced by ET-1 is unlikely to be mediated by GSK3 to any significant extent.
Key aspects of the hypertrophic response are increases in cell size and myofibrillar content. Exposure of cardiac myocytes to 1-azakenpaullone for 24 h resulted in increases in cell area that resulted primarily from elongation rather than any increase in cell width (Fig. 5C -G). In contrast, cells exposed to established hypertrophic agonists such as phenylephrine (Fig. 5C -G) or ET-1 [62] displayed more uniform increases in both length and width. Li + ions have been used extensively as inhibitors of GSK3 (see, for example, [18] ) and may be reasonably effective under physiological ATP/Mg 2+ concentrations [64] .
Myocytes exposed to Li + also showed evidence of increased cell area and elongation (Fig. 5C and D) but the effect was less than with 1-azakenpaullone (possibly reflecting the relative potencies of the inhibitors). Confusingly, cardiospecific overexpression of GSK3$ in vivo also causes an increase in length:width ratio [53] . Myocyte elongation has been previously observed with the gp130-coupled cytokine receptor agonist, cardiotrophin-1 [74] . As pointed out by Wollert et al. [74] , Rho kinases [75] [76] [77] and PDK1 [78, 79] ) are also inhibited [36, 80] . However, it is the activation of these kinases that is considered to be pro-hypertrophic.
In conclusion, although ET-1 and insulin do both promote phosphorylation of GSK3 in cardiac myocytes (as previously reported [18] ), the signalling pathways involved differ, with ET-1 operating primarily the ERK1/2 cascade and insulin signalling through PI3K.
Inhibition of GSK3 by 1-azakenpaullone does produce changes in cardiac myocyte morphology, but these changes differ from those produced by ET-1 or phenylephrine. 1-Azakenpaullone induces changes in gene expression but this are dissimilar from those induced by ET-1, which (in any case) promotes a much more extensive spectrum of changes (A. Clerk et al., manuscript submitted). Furthermore, although previous work in cardiac myocytes has focussed largely on GSK3$, GSK3" is functional in these cells and should not be ignored. In the broader context, PKB/Akt is generally viewed as a 'pro-hypertrophic' kinase in the heart [78, 79] . However, PKB/Akt is strongly activated by insulin in cardiac myocytes [63] , and GSK3"(Ser-21) and GSK3$(Ser-9) become rapidly phosphorylated (Fig.   28 1C-E), but insulin does not cause myocyte enlargement [62] . Viewed as a whole, these divergent results are difficult to rationalise in terms of the hypothesis that inhibition of GSK3 represents a primary stimulus to cardiac myocyte hypertrophy [20] or that ET-1-induced hypertrophy is mediated by inhibition of GSK3 [18] .
relative to control; # p<0.05 relative to insulin (one-way ANOVA with Tukey post-test, n=3 independent myocyte preparations). 
